PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: EastHORN Clinical Services in CEE

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

EastHORN Names Gordon As New Global Head of Business Development - Eastern European specialist contract research organization (CRO) EastHORN Clinical Services in CEE announces the appointment of Iain Gordon as its new Global Head of Business Development
EastHORN Names Gordon As New Global Head of Business Development

 

NewswireToday - /newswire/ - Prague, Czech Republic, 2013/07/24 - Eastern European specialist contract research organization (CRO) EastHORN Clinical Services in CEE announces the appointment of Iain Gordon as its new Global Head of Business Development.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Gordon has been closely involved in clinical research in CEE since the late 90’s and has been an integral part of the exponential growth in clinical trials that the region has enjoyed since then. During this period he was most recently at the Russian/Swiss CRO PSI, as Head of Business Development, Europe. Before that he was at Pharm-Olam, as VP of Commercial and Corporate Affairs, and prior to that spent 7 years at Inveresk Research. Based in the UK, Gordon is a 15-year veteran of CRO business development in Central and Eastern Europe.

Alan Wood, PhD, EastHORN’s Executive Chairman, said: “We are very pleased to have been able to attract a person of Iain Gordon’s calibre to lead our Business Development efforts. We have ambitious growth plans within our region and Iain will be a key player in our senior management team.”

Iain Gordon said: “I am delighted to be joining EastHORN at this important stage in the company’s development. Since joining the CRO industry in the 90's I have been continually impressed with the quality and speed of clinical work in CEE. In an industry where timelines are absolutely key, but deadlines are often missed, I have lost count of the times that CEE operations and sites have saved the day. As this region matures it now offers the best of both worlds, combining experience and dynamic enrolment, continually outperforming some of the more exotic and less predictable regions that have started to offer clinical services more recently."

Founded in Prague in 2004 (as Unimed s.r.o), EastHORN is today one of the leading CROs in Central and Eastern Europe. We operate in over 15 countries in the region with an experienced staff comprised almost entirely of physicians and PhDs.

EastHORN’s clients include global pharmaceutical, biotechnology, and medical device companies with products across a broad range of therapeutic areas.

Our corporate culture values an ethical approach in business. Our biggest asset is our staff and we are focused on attracting and developing the best talent available in CEE through a culture of empowerment and trust. EastHORN Clinical Services in CEE’s management team is highly experienced in the healthcare industry and is committed to providing you with the best service in the business.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: EastHORN Clinical Services in CEE

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


EastHORN Names Gordon As New Global Head of Business Development

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Cristina Tatareanu - EastHORN.eu 
+40 723303105 info[.]easthorn.eu
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any EastHORN Clinical Services in CEE securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From EastHORN Clinical Services in CEE / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)